Akebia Therapeutics, Inc. (AKBA) has 8 SEC Form 4 insider filings on record in the last 90 days. No insider purchases were filed — 1 sales totalling $62K. Most recent filing: Aug. 10, 2026.
| Date | Insider | Value | Shares | Stake | Pre-planned | Links |
|---|---|---|---|---|---|---|
| Aug. 10, 2026 filed Aug. 6, 2026 | Butler John P. CEO and President | $220,500 | 700,000 | +200% | No | |
|
|
||||||
| July 1, 2026 filed June 29, 2026 | Ostrowski Erik SVP, CFO, CBO & Treasurer | −$62,181 | 56,019 | −8% | Yes | |
|
|
||||||
| June 22, 2026 filed June 17, 2026 | Wolf Myles Director | $0 | 89,300 | +199% | No | |
|
|
||||||
| June 22, 2026 filed June 17, 2026 | Smith Cynthia Director | $0 | 89,300 | +199% | No | |
|
|
||||||
| June 22, 2026 filed June 17, 2026 | ROGERS MICHAEL W Director | $0 | 89,300 | +199% | No | |
|
|
||||||
Showing the 5 most recent of 8 filings in the last 90 days.
Form 4 is the filing company officers, directors and 10% shareholders must submit to the SEC within two business days of trading their own company's stock. Open-market purchases generally carry more signal than sales, which are often scheduled in advance. More on how this works.
Real-time Telegram alerts the moment a Form 4 is filed. Filings shown here are delayed by 72 hours.
Start free